Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Novartis    NOVN   CH0012005267

NOVARTIS (NOVN)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
10/11/2018 10/12/2018 10/15/2018 10/16/2018 10/17/2018 Date
81.46(c) 82(c) 82.46(c) 84.08(c) 84.28 Last
7 036 906 4 666 255 3 194 554 4 862 407 5 184 216 Volume
-3.62% +0.66% +0.56% +1.96% +0.24% Change
More quotes
Financials (USD)
Sales 2018 52 353 M
EBIT 2018 12 653 M
Net income 2018 11 669 M
Debt 2018 14 552 M
Yield 2018 3,48%
Sales 2019 53 668 M
EBIT 2019 13 510 M
Net income 2019 9 221 M
Debt 2019 12 375 M
Yield 2019 3,60%
P/E ratio 2018 14,62
P/E ratio 2019 20,87
EV / Sales2018 4,33x
EV / Sales2019 4,18x
Capitalization 212 B
More Financials
Company
Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products.It operates through the following segments: Innovative Medicines, Alcon, Sandoz, and Corporate.The Innovative Medicines segment researches, develops, manufactures, distributes and... 
Sector
Pharmaceuticals
Calendar
10/18Earnings Release
More about the company
Surperformance© ratings of Novartis
Trading Rating : Investor Rating :
More Ratings
Latest news on NOVARTIS
10/17Beset by copies, Roche gets sales boost from China
RE
10/17Samsung launches third rival to AbbVie's Humira drug in EU
RE
10/16NOVARTIS : to Present Extension Phase 3 Data on Cosentyx
DJ
10/16NOVARTIS : 5-year data in psoriatic arthritis and ankylosing spondylitis reinfor..
GL
10/15AstraZeneca will keep UK investment freeze if no Brexit clarity
RE
10/15AstraZeneca will keep UK investment freeze if no Brexit clarity
RE
10/15NOVARTIS AG : quaterly earnings release
10/11ABBVIE : Resolves Humira Patent Dispute With Sandoz
DJ
10/11NOVARTIS : Sandoz announces global resolution of biosimilar adalimumab patent di..
AQ
10/11NOVARTIS : Sandoz announces global resolution of biosimilar adalimumab patent di..
GL
More news
Sector news : Pharmaceuticals - NEC
10/17CONSTELLATION BRANDS : Corona brewer Constellation Brands' CEO Rob Sands to step..
RE
10/17Health Care Up On Stronger Earnings -- Health Care Roundup
DJ
10/17PFIZER : Looks to Reduce Headcount by 2%--Reports
DJ
10/17PFIZER : to cut around 2 percent of jobs through early next year
RE
10/17ANTHEM : HealthCore, Novo Nordisk to Study Diabetes Treatment Compared With Othe..
DJ
More sector news : Pharmaceuticals - NEC
MarketScreener Strategies on NOVARTIS 
NOVARTIS - 09/03
Technically solid
BUY
NOVARTIS - 04/30
Underpinned by a support level
BUY
More Strategies
Latest Tweets
10/17Amgen, Novartis and Banner Alzheimer's Institute Team on 2 Alzheimer's Preven.. 
10/17Papillary Thyroid Cancer - 2018 Pipeline Insights featuring Novartis, Pfizer,.. 
10/17A second round of consultation on the masterplan for the former Novartis site..
2
10/16ADRs End Slightly Higher; AstraZeneca PLC, British American Tobacco and Novar.. 
10/16Amgen, Novartis kick off fight for AbbVie blockbuster drug in EU  
More tweets
Qtime:167
News from SeekingAlpha
10/17Notable earnings before Thursday?s open 
10/17A CLOSER LOOK : Conatus' Prospects With Severe Portal Hypertension Post Subgroup.. 
10/16Neon Therapeutics Is An Emerging Player In Personalized Immunotherapy With Ca.. 
10/1610 'Safer' Dividend Healthcare WallStars Gain 12-23% Per Broker October Targe.. 
10/16Novartis' Cosentyx shows long-term treatment effect in psoriatic arthritis an.. 
Chart NOVARTIS
Duration : Period :
Novartis Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVARTIS
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 91,6 $
Spread / Average Target 7,9%
EPS Revisions
Managers
NameTitle
Vasant Narasimhan Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Werner Kirsch Chief Financial Officer
John Tsai Chief Medical Officer
Srikant Madhav Datar Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS0.07%212 170
JOHNSON & JOHNSON-4.19%359 141
PFIZER20.87%256 643
ROCHE HOLDING LTD.-4.56%204 777
MERCK AND COMPANY23.44%185 661
AMGEN12.47%127 765